Medpace Holdings Inc (MEDP) Stock AnalysisMEDPMedpace Holdings Inc

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Medpace Holdings Inc is a good buy right now, with a current price of $612.05 and a forward P/E ratio of 31.95, indicating strong growth potential. The company has demonstrated solid financial performance, with a year-to-date change of +7.19% and a 1-year change of +16.05%. The main risk is the CEO's recent share sell-off, where he sold 15,978 shares for $10 million, which could raise concerns among investors, but this represents only 3% of his holdings and he still retains a significant stake.

7 analysts cover MEDP: 1 rate it Buy, 6 Hold and 0 Sell. The average price target is 569.17.